PM-43I is a potent STAT6 inhibitor and can reduce STAT6 phosphorylation level. PM-43I can be used in allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease and cancer research[1].
PM-43I (0.05-5 μM; 2 h) inhibits IL-4 stimulated phosphorylation of STAT6 in Beas-2B immortalized human airway cells[1].
PM-43I (intranasal administration; 5 μg per mouse; every other day; 18 d) activity is restricted to the lung by intranasal administration[1].
References:
[1]. John S. Mcmurray, et al. Stat6 inhibitors. WO2014182928A2.